lifestyle.celebhomes.net
Home
Sample Page
Author:
Ensysce Biosciences
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 15, 2026
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 12, 2026
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
May 8, 2026
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
April 16, 2026
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 7, 2026
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
March 31, 2026
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 28, 2026
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 8, 2026
Ensysce Biosciences Issues Annual Shareholder Letter
January 5, 2026
1
2
Next Page
→